Combinations of immunotherapies in the first-line treatment of urothelial cancer: systematic review and meta-analysis of individual patient data

Platinum-based chemotherapy represents the standard of care for the first-line treatment of advanced urothelial carcinoma (mUC). The benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy has recently been investigated. The authors conducted a meta-analysis of individual patient data (IPD) from phase 3 clinical trials comparing ICI-based therapies.